Date Name Title Filing Type Shares Traded Price Total Held
Jan 04, 2024
Director, Bd. Co-Chair, President & CSO
Director, Bd. Co-Chair, President & CSO Form 4 Other acquisition or disposition -- -- 158,410
Jan 02, 2024
Director, Bd. Co-Chair, President & CSO
Director, Bd. Co-Chair, President & CSO Form 4 Open market or private sale of non-derivative or derivative security 16,848 $900.00 180,000
Dec 13, 2023
Director, Bd. Co-Chair, President & CSO
Director, Bd. Co-Chair, President & CSO Form 4 Other acquisition or disposition -- -- 5,889
Dec 13, 2023
Director, Bd. Co-Chair, President & CSO
Director, Bd. Co-Chair, President & CSO Form 4 Other acquisition or disposition -- -- 196,848
Dec 13, 2023
Director, Bd. Co-Chair, President & CSO
Director, Bd. Co-Chair, President & CSO Form 4 Other acquisition or disposition -- -- 121,071
Dec 13, 2023
Director, Bd. Co-Chair, President & CSO
Director, Bd. Co-Chair, President & CSO Form 4 Other acquisition or disposition -- -- 158,410
Dec 11, 2023
Director, Bd. Co-Chair, President & CSO
Director, Bd. Co-Chair, President & CSO Form 4 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 25,155 -- 765,327
Dec 11, 2023
Director, Bd. Co-Chair, President & CSO
Director, Bd. Co-Chair, President & CSO Form 4 Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 12,841 $844.09 752,486
Dec 11, 2023
Director, Bd. Co-Chair, President & CSO
Director, Bd. Co-Chair, President & CSO Form 4 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 25,155 -- --
Dec 14, 2010
Director, EVP CSO & Pres Regn Res Labs
Director, EVP CSO & Pres Regn Res Labs Form 4 Grant, award or other acquisition pursuant to Rule 16b-3(d) 3,264 -- 3,264

* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.